Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RK-582 in unresectable metastatic colorectal cancer
NCT06853496Phase 1Recruiting
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of RK-582 in colorectal cancer (CRC). Primary endpoints: Percentage of dose-limiting toxicity at 35 days and Number of participants with adverse events at 1 year. Started Mar 2025; status: recruiting.
02
Drugs
RK-582
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06853496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06853496.